San Diego, CA -- (ReleaseWire) -- 08/04/2016 --Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCQB:INNV) announced today it has re-appointed PT Laras Bumi Resources ("LB Resources") as its agent for the distribution of its product Zestra® to increase Female Sexual Arousal and Desire and Satisfaction in select Asian countries.  Based in Indonesia ("LB Resources") has extensive distribution in Japan, China, Indonesia and South Korea. LB Resources projects an initial ordering annual volume close to 150,000 units a year.

Prior to its acquisition by Innovus Pharma, Semprae Labs shipped over 1 million units of Zestra® to Asia.

Since Zestra® is already registered as a cosmetic in China and South Korea and is well known, the Company expects to start commercial shipments as early as September 2016.

"This partnership is an important one for the Company as it allows us to resume sales of Zestra® to multiple Asian countries where the product is already registered.  Our goal is to quickly get back to the one million units of sales a year previously achieved by the product," said Dr. Bassam Damaj, President & CEO of Innovus.

About Zestra® and FSI/AD
Zestra® is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. Zestra® is the first NHP product to receive approval for the indication of FSI/AD in Canada as an NHP. To date, the Company believes that no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress. Published papers on the FSI/AD market size estimate it to be equal or larger than the market for erectile dysfunction in males, and possibly larger. Zestra® is currently available in the United States, Canada and Morocco.

For more information visit http://www.zestra.com

About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and hopefully, eventually from FlutiCare™ OTC for Allergic Rhinitis for which an ANDA has been submitted to the U.S. Food and Drug Administration.

For more information, go to:
www.innovuspharma.com
www.zestra.com
www.ejectdelay.com
www.myvesele.com
www.sensumplus.com
www.myandroferti.com
www.beyondhumantestosterone.com
www.getbeyondhuman.com
www.trybeyondhuman.com
www.recalmax.com

About PT Laras Bumi Resources
Established in 1987 and based in Indonesia, PT Laras Bumi Resources Food & Health Products Division has developed extensive distribution, compliance and regulatory expertise in Asia including extensive affiliations in Greater China, Korea, Japan, Russia, Asiana Indonesia and Singapore.

For more information please visit: www.lbresources.com

Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority, to successfully commercialize its products and to achieve its other development, commercialization, meeting its sales projections, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein.  Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
Tel: 410-825-3930

Source: UPTICK Newswire